Intellia Therapeutics Inc sell The Goldman Sachs Group, Inc.
Start price
28.02.25
/
50%
€9.21
Target price
28.02.26
€8.65
Performance (%)
19.35%
End price
01.03.26
€10.99
Summary
This prediction ended on 01.03.26 with a price of €10.99. The prediction closed with a disappointing performance of 19.35%. The_Goldman_Sachs_Gr has a follow-up prediction for Intellia Therapeutics Inc where he still thinks Intellia Therapeutics Inc is a Sell. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | 4.102% | 4.102% | 21.717% |
| iShares Core DAX® | -1,06 % | 5,01 % | 6,60 % |
| iShares Nasdaq 100 | -2,39 % | 0,86 % | 25,79 % |
| iShares Nikkei 225® | -4,36 % | 1,21 % | 41,31 % |
| iShares S&P 500 | -1,78 % | 1,39 % | 21,04 % |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "sell" rating re-affirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $9.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten
Current prediction by The_Goldman_Sachs_Gr for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€11.14
28.04.26
28.04.26
-
28.04.27
28.04.27
-4.31%
20.08.26
20.08.26
